Cargando…
CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce the risk of cardiovascular events and all-cause mortality in patients at high risk of cardiovascular disease (CVD). Due to high costs and unknown long-term adverse effects, critical evaluation of patients considered for PCSK9 in...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023332/ https://www.ncbi.nlm.nih.gov/pubmed/29861477 http://dx.doi.org/10.3390/diseases6020045 |